


## CYP17-IN-1

Cat. No.:	HY-101516
CAS No.:	2093317-51-0
Molecular Formula:	C <sub>18</sub> H <sub>17</sub> FN <sub>2</sub> S
Molecular Weight:	312.4
Target:	Cytochrome P450
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	CYP17-IN-1 (compound 9c) is a potent and orally active CYP17 inhibitor against rat and human CYP17 with IC <sub>50</sub> s of 15.8 and 20.1 nM <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 15.8 nM (Rat CYP17), 20.1 nM (Human CYP17) <sup>[1]</sup>
<b>In Vitro</b>	CYP17-IN-1 (compound 9c) exhibits an IC <sub>50</sub> value of 8.5 μM against CYP3A4 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	CYP17-IN-1 (compound 9c) reduces plasma testosterone level in a dose-dependent manner in Sprague-Dawley rats <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Wang M, et al. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors. Eur J Med Chem. 2017 May 26;132:157-172.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA